Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 1, 2004

 


 

PRO-PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Nevada   000-32877   04-3562325

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

189 Wells Avenue, Newton, Massachusetts   02459
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 559-0033

 

Not Applicable

(Former name or former address, if changed since last report.)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

(b)

 

Charles F. Harney, Chief Financial Officer of Pro-Pharmaceuticals, Inc., resigned effective November 1, 2004. Due to other commitments, Mr. Harney could not provide services to the Company on a full-time basis. We are appointing an executive search committee, which will include at least one person from our Board of Directors, to select a new full-time CFO. Mr. Harney has agreed to provide financial consulting services for a reasonable period while Pro-Pharmaceuticals conducts the executive search.


SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

PRO-PHARMACEUTICALS, INC.

By:

 

/s/ David Platt


   

David Platt

   

President and Chief Executive Officer

 

Date: November 5, 2004